{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:29:49Z","timestamp":1787761789975,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR) mutations are a common driver of oncogenesis in non-small cell lung cancer (NSCLC). Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has shown promise as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated NSCLC. However, the comparative efficacy and safety of lazertinib in this setting have not been thoroughly investigated. This study aims to evaluate the efficacy and safety of lazertinib for EGFR-mutated locally advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We performed a search of PubMed, ProQuest, EBSCO, and ScienceDirect to identify eligible studies based on the PICOTS-SD criteria. The meta-analysis of overall survival (OS), progression-free survival (PFS), and adverse effects was performed using RevMan 5.4 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This review included a total of three randomized controlled trials. The pooled analysis revealed significant differences in PFS, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI]: 0.37\u20130.53). However, OS showed no significant differences, with an HR of 0.82 (95% CI: 0.64\u20131.06). Paresthesia occurred significantly more frequently in the lazertinib group (odds ratio [OR]: 11.30; 95% CI: 7.30\u201317.49). In contrast, the incidence of diarrhea and increases in Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) levels were significantly higher in the gefitinib group, with ORs of 0.52 (95% CI: 0.39\u20130.70), 0.35 (95% CI: 0.25\u20130.50), and 0.32 (95% CI: 0.22\u20130.47), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lazertinib demonstrated a greater therapeutic benefit for patients with EGFR-mutated advanced NSCLC compared to first-generation EGFR-TKIs. Further research is needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/hemoncstem.hemoncstem-d-24-00041","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:00:10Z","timestamp":1750399210000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lazertinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"prefix":"10.4103","volume":"18","author":[{"given":"Louis Fabio Jonathan","family":"Jusni","sequence":"first","affiliation":[{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Ricardo","family":"Yonatan","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas Daniel","family":"Widjanarko","sequence":"additional","affiliation":[{"name":"Fatima Hospital, Delta Pawan Subdistrict, Ketapang Regency, West Kalimantan, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rio Gusta Notario","family":"Besri","sequence":"additional","affiliation":[{"name":"Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20250728","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","journal-title":"Contemp Oncol (Pozn)"},{"key":"R2-20250728","doi-asserted-by":"crossref","first-page":"144","DOI":"10.36497\/jri.v43i2.455","article-title":"Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia","volume":"43","author":"Andarini","year":"2023","journal-title":"J Respirologi Indones"},{"key":"R3-20250728","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R4-20250728","first-page":"343","article-title":"Characteristics of non-small cell lung carcinoma and the result of epidermal (Karakteristik Kanker Paru Jenis Karsinoma Bukan Sel Kecil Dan Hasil Pemeriksaan Epidermal Growth Factor Receptor)","volume":"02","author":"Koswara","year":"2022","journal-title":"J Heal Dent Sci"},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3390\/curroncol31040146","article-title":"Real-world outcomes of patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer in Canada using data extracted by large language model-based artificial intelligence","volume":"31","author":"Moulson","year":"2024","journal-title":"Curr Oncol"},{"key":"R6-20250728","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0063-y","article-title":"Cell death-based treatment of lung adenocarcinoma article","volume":"9","author":"Denisenko","year":"2018","journal-title":"Cell Death Dis"},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.semtcvs.2014.09.002","article-title":"The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know","volume":"26","author":"Eguchi","year":"2014","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"R8-20250728","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S1470-2045(12)70291-7","article-title":"Squamous-cell carcinomas of the lung: Emerging biology, controversies, and the promise of targeted therapy","volume":"13","author":"Drilon","year":"2012","journal-title":"Lancet Oncol"},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00432-019-03079-8","article-title":"The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients","volume":"146","author":"Wang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13100273","article-title":"Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)","volume":"13","author":"O\u2019Leary","year":"2020","journal-title":"Pharmaceuticals"},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jtho.2017.11.128","article-title":"Geographic Variation in EGFR mutation frequency in lung adenocarcinoma may be explained by interethnic genetic variation","volume":"13","author":"Soraas","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0000000000000481","article-title":"Updated frequency of EGFR and KRAS mutations in nonsmall-cell lung cancer in Latin America: the Latin-American consortium for the investigation of lung cancer (CLICaP)","volume":"10","author":"Arrieta","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3892\/ol.2015.3414","article-title":"Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma","volume":"10","author":"Soh","year":"2015","journal-title":"Oncol Lett"},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"75712","DOI":"10.18632\/oncotarget.20095","article-title":"EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer","volume":"8","author":"Nan","year":"2017","journal-title":"Oncotarget"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.21037\/tcr.2018.10.06","article-title":"EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients","volume":"8","author":"Karachaliou","year":"2019","journal-title":"Transl Cancer Res"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.2147\/OTT.S227032","article-title":"Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data","volume":"14","author":"Chung-Shien","year":"2021","journal-title":"Onco Targets Ther"},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"107509","DOI":"10.1016\/j.lungcan.2024.107509","article-title":"Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: long-term follow-up results from LAS ER201","volume":"190","author":"Chul Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"107213","DOI":"10.1016\/j.lungcan.2023.107213","article-title":"Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: a real-world multicenter study","volume":"180","author":"Kim","year":"2023","journal-title":"Lung Cancer"},{"key":"R19-20250728","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2023.06.016","article-title":"Lazertinib versus gefitinib tyrosine kinase inhibitors in treatment-na\u00edve patients with EGFR-mutated advanced NSCLC: analysis of the Asian subpopulation in LAS ER301","volume":"18","author":"Reungwetwattana","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R20-20250728","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R21-20250728","first-page":"1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4097\/kja.21080","article-title":"Self-learning software tools for data analysis in meta-analysis","volume":"74","author":"Tantry","year":"2021","journal-title":"Korean J Anesthesiol"},{"key":"R23-20250728","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4143\/crt.2022.264","article-title":"Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015","volume":"55","author":"Jeon","year":"2023","journal-title":"Cancer Res Treat"},{"key":"R24-20250728","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0000000000000696","article-title":"Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer","volume":"33","author":"Gong","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"R25-20250728","first-page":"1589","article-title":"Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation","volume":"38","author":"Li","year":"2022","journal-title":"Pakistan J Med Sci"},{"key":"R26-20250728","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Target Oncol"},{"key":"R27-20250728","first-page":"i29","article-title":"Determining the prevalence of EGFR mutations in Asian and Russian Patients (PTS) with advanced non-small-cell lung cancer (ANSCLC) of adenocarcinoma (ADC) and non-ADC histology: ignite study","volume":"26","author":"Han","year":"2015","journal-title":"Ann Oncol"},{"key":"R28-20250728","first-page":"1","article-title":"Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"R29-20250728","first-page":"1","article-title":"Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"R30-20250728","first-page":"1","article-title":"EGFR-mutated squamous cell lung cancer and its association with outcomes","volume":"11","author":"Jin","year":"2021","journal-title":"Front Oncol"},{"key":"R31-20250728","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1097\/JTO.0000000000000571","article-title":"Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition","volume":"10","author":"Levin","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R32-20250728","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"R33-20250728","first-page":"1","article-title":"Clinical outcomes of EGFR\u2014TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21","author":"Yu","year":"2016","journal-title":"Chin J Cancer"},{"key":"R34-20250728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0228925","article-title":"Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study","volume":"15","author":"Yoon","year":"2020","journal-title":"PLoS One"},{"key":"R35-20250728","first-page":"3887","article-title":"Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer","volume":"18","author":"Hong","year":"2019","journal-title":"Oncol Lett"},{"key":"R36-20250728","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"376","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"R39-20250728","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R40-20250728","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:05:38Z","timestamp":1787760338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-24-00041","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}